<SEC-DOCUMENT>0001387131-17-004745.txt : 20170925
<SEC-HEADER>0001387131-17-004745.hdr.sgml : 20170925
<ACCEPTANCE-DATETIME>20170925065644
ACCESSION NUMBER:		0001387131-17-004745
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170925
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170925
DATE AS OF CHANGE:		20170925

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		171098586

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>txmd-8k_092517.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: none">Washington,
D.C. 20549</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"></P>

<HR ALIGN="CENTER" NOSHADE STYLE="color: Black; width: 30%; height: 1pt; margin-top: 0; margin-bottom: 0">
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">FORM
8-K</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PURSUANT
TO SECTION 13 OR 15(d) OF THE</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">SECURITIES
EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): September 25, 2017</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TherapeuticsMD,
    Inc.</B></FONT></TD>
    <TD STYLE="width: 30%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 30pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in its Charter)</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-00100</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>87-0233535</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                         or Other</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jurisdiction
        of Incorporation)</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File Number)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer<BR>
    Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6800
                                         Broken Sound Parkway NW, Third Floor</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boca
        Raton, FL 33487</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 5.4pt; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of Principal Executive Office) (Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
telephone number, including area code: (561) 961-1900</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: justify; text-indent: -0.25in">&#9744;&nbsp;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;
230-405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&nbsp;&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT>&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD NOWRAP STYLE="width: 1in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
                                         3.01</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of Delisting of Failure to
Satisfy a Continued Listing Rule or Standard; Transfer of Listing. </FONT></B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On September 25, 2017, TherapeuticsMD, Inc., a Nevada corporation (the &ldquo;Company&rdquo;), in accordance with authority granted by the Company&rsquo;s board of directors, provided written notice to the NYSE American LLC (the &ldquo;NYSE American&rdquo;) of its intention to voluntarily delist its common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), from the NYSE American and to transfer the listing of its Common Stock to the Nasdaq Global Select Market of The Nasdaq Stock Market LLC (the &ldquo;Nasdaq&rdquo;).  The Company expects the listing and trading of its Common Stock on the NYSE American will cease at market close on October 8, 2017 and that trading of its Common Stock will commence on the Nasdaq on October 9, 2017.  The Common Stock has been approved for listing on the Nasdaq, with the Common Stock continuing to trade under the symbol &ldquo;TXMD.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD NOWRAP STYLE="width: 1in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
                                         7.01</B></FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Regulation FD Disclosure.</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On September 25, 2017, the Company issued a press release announcing the transfer of its Common Stock listing
to the Nasdaq. The press release is furnished as Exhibit&nbsp;99.1 hereto. The information included in this Item 7.01 and in Exhibit
99.1 shall not be deemed &ldquo;filed&rdquo; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended
(&ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference
in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD NOWRAP STYLE="width: 1in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
                                         9.01.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
                                         Statements and Exhibits.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in; text-align: right">(d)</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 1in"><I>Exhibits.</I></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Exhibit<BR>
    <U>Number</U></TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>99.1</TD>
    <TD>Press Release from TherapeuticsMD, Inc., dated September 25, 2017, entitled &ldquo;TherapeuticsMD Announces Move to Nasdaq Global Select Market&rdquo;.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Date:
September 25, 2017</TD>
    <TD COLSPAN="3">THERAPEUTICSMD, INC.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%">By:</TD>
    <TD STYLE="width: 28%; border-bottom: Black 1pt solid"><I>/s/ Daniel A. Cartwright</I></TD>
    <TD STYLE="width: 16%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD COLSPAN="2">Daniel A. Cartwright</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD COLSPAN="2">Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 1in">Exhibit<BR>
    <U>Number</U></TD>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><A HREF="ex99-1.htm">99.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ex99-1.htm">Press Release from TherapeuticsMD, Inc., dated September 25, 2017, entitled &ldquo;TherapeuticsMD Announces Move to Nasdaq Global Select Market&rdquo;.</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 1.5in; text-indent: -1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED SEPTEMBER 25, 2017
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><A HREF="txmd-8k_092517.htm">TherapeuticsMD, Inc. 8-K</A></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 4pt 0 0 4in; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05in 0 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">FOR
IMMEDIATE RELEASE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>TherapeuticsMD Announces Move to Nasdaq Global Select Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>BOCA
RATON, Fla. </B>&#8211; <B>September 25, 2017</B> &#8211; TherapeuticsMD, Inc. (NYSE American: TXMD), an innovative women&rsquo;s healthcare company, today announced that it will voluntarily move its stock exchange listing to the Nasdaq Global Select Market from the NYSE American LLC.  The Company expects its common stock will begin trading on the Nasdaq Global Select Market on October 9, 2017 and its shares will continue to trade under the ticker symbol &ldquo;TXMD&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;Nasdaq is a great fit for TherapeuticsMD and represents the home of the world&rsquo;s leading publicly traded biopharmaceutical companies,&rdquo; said Robert G. Finizio, CEO of TherapeuticsMD. &ldquo;We believe this move will enhance TherapeuticsMD&rsquo;s visibility to all types of institutional investors and provide efficient liquidity for our shareholders.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&ldquo;We are proud to welcome TherapeuticsMD to Nasdaq&rsquo;s family of the world&rsquo;s largest and most
innovative companies,&rdquo; said Nelson Griggs, President of the Nasdaq Stock Exchange. &ldquo;A Nasdaq listing will give TherapeuticsMD
exposure to leading indexes in the investment community and will join other great pharmaceutical and biotechnology companies on
Nasdaq. We look forward to working with and supporting TherapeuticsMD as it grows and achieves new milestones in women&rsquo;s
health.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company has notified the NYSE American that it will voluntarily delist its common stock from the NYSE American.  The last day of trading of the Company&rsquo;s common stock on the NYSE American is expected to be on October 8, 2017.  Until the Company&rsquo;s common stock begins trading on Nasdaq, the Company&rsquo;s common stock will continue to trade on the NYSE American under the ticker symbol &ldquo;TXMD&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>About
TherapeuticsMD, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA&trade; technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company&rsquo;s late stage clinical pipeline includes two phase 3 product candidates: TX-001HR for treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause and TX-004HR for treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD<sup>&reg;</sup> and BocaGreenMD<sup>&reg;</sup> brands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><I>This press release by&nbsp;TherapeuticsMD, Inc.&nbsp;may contain forward-looking statements. Forward-looking
statements may include, but are not limited to, statements relating to TherapeuticsMD&rsquo;s objectives, plans and strategies
as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects,
projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such
as &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;should,&rdquo; &ldquo;intends,&rdquo;
&ldquo;plans,&rdquo; &ldquo;will,&rdquo; &ldquo;expects,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;positioned,&rdquo;
&ldquo;strategy&rdquo; and similar expressions and are based on assumptions and assessments made in light of management&rsquo;s
experience and perception of historical trends, current conditions, expected future developments and other factors believed to
be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company
undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are
outside of the company&rsquo;s control. Important factors that could cause actual results, developments and business decisions
to differ materially from forward-looking statements are described in the sections titled &ldquo;Risk Factors&rdquo; in the company&rsquo;s
filings with the&nbsp;Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports
on Form 10-Q, as well as reports on Form 8-K, and include the following: the company&rsquo;s ability to resolve the deficiencies
identified by the&nbsp;FDA&nbsp;in the company&rsquo;s new drug application for its TX-004HR product candidate and the time frame
associated with such resolution; whether the company will be able to prepare an amended NDA for its TX-004HR product candidate
and, if prepared, whether the&nbsp;FDA&nbsp;will accept and approve the NDA; the company&rsquo;s ability to maintain or increase
sales of its products; the company&rsquo;s ability to develop and commercialize its hormone therapy drug candidates and obtain
additional financing necessary therefor; whether the company will be able to prepare an NDA for its TX-001HR product candidate
and, if prepared, whether the&nbsp;FDA&nbsp;will accept and approve the NDA; the length, cost and uncertain results of the company&rsquo;s
clinical trials, including any additional clinical trials that the&nbsp;FDA&nbsp;may require in connection with TX-004HR; the potential
of adverse side effects or other safety risks that could preclude the approval of the company&rsquo;s hormone therapy drug candidates;
the company&rsquo;s reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability
of reimbursement from government authorities and health insurance companies for the company&rsquo;s products; the impact of product
liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company&rsquo;s
common stock and the concentration of power in its stock ownership; and the transfer of the company&rsquo;s stock listing from
the NYSE American to the Nasdaq Global Select Market. PDF copies of the company&rsquo;s historical press releases and financial
tables can be viewed and downloaded at its website:&nbsp;www.therapeuticsmd.com/pressreleases.aspx</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">#
# #</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.35pt; text-indent: -5.35pt; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><U>Investor
Contact</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 292.3pt 0 0; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">David
DeLucia</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 292.3pt 0 0; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Director,
Investor Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 274.5pt 0 0; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">561-961-1900<BR>
David.DeLucia@TherapeuticsMD.com</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 274.5pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 274.5pt 0 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 274.5pt 0 0">&nbsp;</P>



<P STYLE="margin: 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  < .\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#J-8^'NL:7
MHM]J \<ZQ(;6WDF"%W&[:I.,[_:J'A#P;K/B?PS:ZL_C76+=IR^8Q([ ;6*]
M=X]*]-\6_P#(FZW_ ->,W_H!K$^$_P#R3C3/K+_Z,:NE59>S;\^R_P CE=*'
MM%'I;N^_J<[XFLWTSQKX M)KM[EK<LKW$I^9\%<L<D_SKM(_'OA66^%DFN6A
MG+;0-Q"D^@;[OZUQ?Q0TV+6/&WA+3IV98;AWCD*G!VEER!^%;?B_P)X<_P"$
M,U 6VE6MM+:VSRPRQ)M=649Y;J<XYSFA\K4>;K_F)<\93Y+:?Y'=USD_C[PI
M;WAM)=<M!*#M.&)4'W8# _.O.]7\37T/P,TEA.ZSWC_8WES\WEJ7!Y]P@'T)
MJ:QUSX56>AKI;6ZSJ4VR3263&1SW;=C(/T/':DJ.EW=^A3KZV5EI?4];>[MT
MLFO&GC^S+&93-N!78!G=GTQS67<>+?#]IID.HS:O:K:3$B*3?GS,'!V@<G!!
MZ5YGX&U59?!WC/1X+B2XL+."9[.212#Y;(_'/3H#CU)I_P ,/ >GZSX?BUC7
M(S>ABT5I!(QV1HK')P.N6W>WYT.E&-W)[ JTI64%NCTW4?$^AZ1"DNH:I;6X
MD4.@=_F8'G(7K^E)H_BC0]?9ETO4[>Y=1DHK88#UVG!Q7'>+M3\%VOB*.VN=
M!?6=9CA6(6]O#YFQ.J@@G&>?0GI7$ZUJ.FV_B#0K_2?#>H>'[^*[19%D@\J.
M1">P[GJ.@R":(T5)=?P_X<4Z[B^EOG_PQ[A+K6F0:@;":^MX[L1F4Q.X!"#J
MQ]N*R[;QYX6N[T6D&MVC3$[5!8@,?0,1@_G7!^)M!B\1_&NVT^YD=;4V*O,J
M,5+JNX[<^YQ78:Y\//#FI:%-9PZ7:VLJQMY$T,85D;J"2.2,]0:GD@K7;U*4
MZDF^5+0ZZN>O/'?A>PO39W.M6J3J=K*"6"GT) ('XUYI%XRU&/X'O)Y[B\6Y
M_LY9\_,%QNSGUVY7-3Z+KGPOTS08M/GMTN9#&!/-+9,SN^.3DC(YZ8Z52HVO
M>[]"7B+VM9:7U/7&U"S73VU W47V-8S*9PX*; ,[L^E+97UKJ-G'=V4\<]O)
MDI)&<JV#@X/U!KQ7PMJ</_".^.M'T^>6;28K26>R,@(*J58$<_A^()[UZ+\,
M?^2<Z/\ [C_^C&J9TN1-_P!;%TZW.TO+];'0'6-.&I/IQO8?ML<?FO!N^8+Z
MX].:\]TGX@6I^(VM1WFOP?V(L*_9-S@1[L)G!QS_ !?K4L*A_CW>*P!4Z8 0
M>XPM9FA>&]$G^+WB/3Y=*LWLX+=&B@:(%$.(^0.W4_G5QA%)W[7(E.<FK=['
M8>+!IGB+P@LZ^(%L+$RJXOHFRIP2N,Y'?C\*Z"TDM['1;=Y+Q&MHH$S<R, &
M4*/F)/KUKB_BC96NG_#"YM;.WCM[>.6+9'&H55S(#P![FL/6]_B;Q#X2\'R3
M/'IQL8[JZ5#CS,(2!^2_^/>U2H<T5KIJ.53EF]-;([FW\?\ A2ZNQ:Q:Y:F4
MG W$JI/LQ&/UK=N[VUL+1[J[N(H+>,9:21@J@?4US^H?#WPOJ&E'3_[(MK=0
MI$<L$861#ZANI/USFN;^(GAJ\A\)Z-;:7;3W]CIDRM<6I<L\R =^Y[CCINX'
M%2HPDTDRW*I&+;2?H=9I_C;PUJMR+:SUFUDF)PJ%MA8^V[&?PK)^(%QJ<,NC
MII4TJ7#S/M6-\;R-I (Z'Z&L'2M3^&_BB[M+6728-/U"-U\N&6$0G<#PNY>&
M^AZ^E=/XL_Y&'PQ_U]G_ -EJXQ49K3ON<V)DYT'KU6J]4;'A[6HM>TB*\C 6
M3[DT?]QQU']?H:YKQ[K]W#$^E:2[BY6/S[F2-L&*,>_8GC]/6DUPW'@S6I-9
ML;<S6-\"MQ O19N=K?B?YGU%-ET6;3_ VKWM^=^J7T9EN&/5>>$_#_/04XQB
MI*?1[?UY?Y&-:K5G3E1VDD[OR2TM_B_#43Q'=W:_#[198[NXBFE-N'E20ASF
M,YR>IJ]_PAE]""]IXHU59@/E,LA=?Q&:S/$?_).M _WK;_T6:]"I2DXQ5N[+
MI4HU:CY^D8]7V\F<AINO:LMS=:#J*1#6(X]]O,.$G7U],]_P/3%=-IYNS91_
M;0OVC^+;TKE?$V?^$\\,>3CSMTF_UV<?TW?K79U%2UDTMS?#<W-*,FWRNWRL
MGKYK8R?%$,EQX3UB&&-I)9+*941!DL2AP .YK'^&5G<V'@'3[:\MY;>=#)NC
ME0JPS(Q&0:ZZBHYO=Y3HY/?YCS_QGIU[=?$+PA<V]I/+!!*QFD2,LL8ROWB.
M!^-=9XEBDG\+:M%#&TDKV<RHBC)8E#@ >M:E%-SO;R!0MS>?^5CRVQ\&W>N?
M!JRTF6)[74H'>>%)U*$.'? (/3()_,&I+7XA7^GVBV>M>#M2;58P$8P0 QRM
MTW9[9]LBO3J*KVM[\RN1[&UN5VTL<7:2>(-4\#:Y+J^E0V=S<6\XMK: $R;"
MAVJP_O9__4*G^&=G<V'@#3;:\MY;>=/-W1RH589D8C(/M76T5+G=-6*5.S3O
MTL>4R2:CX#^(&LZM<:+=:CIVJ89+BT3>T?.=I';\2.@-4/%^I^(/&3:1)9^&
M]0M]*@O$?=-$?,=O[VT=% SSTYZU[+15JK9IVU(=!M./-H>/>+'U>'XSV]SH
MD237D%@)/(=L>:@W;E^I&<5I:C\0M<U6RDTS1O">J0ZI,IC+3IA82>"<^WJ<
M"IIO^2^V_P#V#3_)J])JI224;J^A$(2DY6E;5GGL/PXQ\+CX:>5!?-_I!EZJ
M)\Y_+ VY].:H6'CK4=#L4TW7_"6HR:A;H(Q+;0ATFQP&S[^V?Z5ZC14>UO\
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
